| | |
C.H. Unnikrishnan 10:20 PM | July 05,2009
The Indian tribunal had cited non-compatibility with domestic patent laws and unaffordable pricing as reasons
|
|
12:07 AM | December 06,2008
Fuel surcharge will be cut by Rs400 to Rs1,950 for flights covering a distance less than 750 km, while it will be Rs2,700 for that above 750 km
|
|
C.H. Unnikrishnan 01:05 AM | November 19,2008
The Swiss drug maker had appealed the rejection by the Chennai patent office of its patent application for blood cancer drug Glivec
|
|
Seema Singh 11:37 PM | June 22,2008
Less than 3% of patients with this type of stroke receive tPA because by the time they reach hospital and get diagnosed, the narrow safety window has closed
|
|
Bhuma Shrivastava and C.H. Unnikrishnan 12:19 AM | January 29,2008
Earlier, Madras HC had allowed the hearing without a tech member on IPAB, at the behest of Novartis AG
|
|
Bhuma Shrivastava 11:35 PM | December 05,2007
Health groups are canvassing with doctors not to prescribe Novartis drugs in protest against the company’s stand on Glivec patent issue
|
|
C.H. Unnikrishnan 12:14 AM | November 23,2007
The challenge weakens Novartis’ petition against an Indian ruling denying patent for the Swiss firm’s cancer drug
|
|
C.H. Unnikrishnan 06:07 PM | November 18,2007
Ruling says IPR Board need not have a technical member on its panel in order to hear Novartis appeal against rejection of its patent application for anti-cancer drug Glivec
|
|
Bhuma Shrivastava 06:30 AM | November 15,2007
Madras High Court says patent appeal will not be heard before S. Chandrasekharan, technical member in appellate body
|
|
C.H. Unnikrishnan 11:44 PM | October 23,2007
The intellectual property appellate board or IPAB will hear Novartis’ appeal against the government refusal grants a patent to its cancer drug Glivec in India
FIND MORE ARTICLES ON:
Glivec DrugCancer
|
|
Bhuma Shrivastava 04:18 PM | August 28,2007
Rejection of cancer drug Glivec had spurred company to seek ouster of former patent controller from panel of the Intellectual Property Appellate Board
|
|
Bhuma Shrivastava 06:34 PM | August 23,2007
The Madras High Court’s decision is a setback for innovation and public health, says Ranjit Shahani, the head of Novartis AG’s Indian operations
|
|
Brian Druker 12:35 AM | August 15,2007
The public sector has a key role in drug R&D. Patenting minor changes to extend monopoly prices spells misuse
FIND MORE ARTICLES ON:
NovartisPatentsGlivec
|
|
Bhuma Shrivastava and C.H. Unnikrishnan 02:12 AM | August 08,2007
A large chunk of these have been filed by the local units of drug majors such as Merck, AstraZeneca and Pfizer
|
|
Daniel Vasella 12:01 AM | May 10,2007
Indian patent laws discriminate against the innovation-focused pharmaceutical industry
|
|